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Abstract This study aimed to assess the efﬁcacy and
tolerability of atorvastatin in Tanner stage (TS) 1 patients
ages 6 to 10 years and TS C2 patients ages 10 to\18 years
with genetically conﬁrmed heterozygous familial hyper-
cholesterolemia (HeFH) and a low density lipoprotein
cholesterol (LDL-C) level of 4 mmol/l (155 mg/dl) or
higher. In this open-label, 8-week study, 15 TS 1 children
were treated initially with atorvastatin 5 mg/day and 24 TS
C2 children with 10 mg/day. Doses were doubled at week
4 if the LDL-C target (\3.35 mmol/l [130 mg/dl]) was not
achieved. The efﬁcacy variables were the percentage
change from baseline in LDL-C, total cholesterol (TC),
triglycerides (TG), high density lipoprotein cholesterol
(HDL-C), very low density lipoprotein cholesterol (VLDL-
C), and apolipoprotein (Apo) A-I and Apo B. Safety
evaluations included clinical monitoring, subject-reported
adverse events (AEs), vital signs, and clinical laboratory
tests. The mean values for LDL-C, TC, VLDL-C, and Apo
B decreased by week 2 among all TS 1 and TS C2 patients,
whereas TG, HDL-C, and Apo A-I varied considerably
from week to week. After 8 weeks, the mean reduction in
LDL-C was -40.7% ± 8.4 for the TS 1 children and
-39.7% ± 10.3 for the TS C2 children. For the TS 1
patients, the mean reductions were -34.1% ± 6.9 for TC
and -6.0% ± 32.1 for TG. The corresponding changes for
the TS C2 patients were -35.6% ± 9.5 for TC and
-21.1% ± 29.7 for TG. Four patients experienced mild to
moderate treatment-related AEs. No serious AEs or dis-
continuations were reported. Overall, no difference in
safety or tolerability was observed between the younger
and older cohorts. Across the range of exposures after
atorvastatin 5 to 10 mg (TS 1) or atorvastatin 10 to 20 mg
(TS C2) doses for 8 weeks, clinically meaningful reduc-
tions in LDL-C, TC, VLDL-C, and Apo were observed
with atorvastatin in pediatric patients who had HeFH.
Atorvastatin also was well tolerated in this population.
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Familial hypercholesterolemia (FH) is a common inherited
autosomal dominant disorder that causes markedly ele-
vated low density lipoprotein cholesterol (LDL-C) levels,
resulting in increased morbidity of coronary heart disease,
with premature death [13]. The severity of atherosclerosis
is correlated with the duration of hypercholesterolemia, and
early initiation of statin therapy for children with FH was
shown to be beneﬁcial in preventing atherosclerosis [18].
Several well-controlled studies have demonstrated that
the short-term safety and effectiveness of the 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMG-CoA) inhib-
itors, or statins, in children and adolescents have been
similar to those observed in adults [1, 7, 14, 16, 19, 21].
Recently, both the American Heart Association (AHA)
[17] and the American Academy of Pediatrics (AAP) [4]
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DOI 10.1007/s00246-011-9885-zhave recommended that target levels for LDL-C as low as
less than 130 mg/dl (3.35 mmol/l) should be set for chil-
dren who are heterozygous for FH, and that statins, among
other classes of drugs, should be considered as a ﬁrst-line
agent. In addition, AHA recommends that after a trial of
dietary changes, drug therapy should ideally be started at
Tanner stage (TS) 2 or higher.
However, for children and adolescents with high-risk
lipid abnormalities who have additional risk factors or
high-risk conditions, in selected cases, clinicians may
consider initiation for children younger than 10 years. The
AAP has recommended that statins be started as early as
8 years of age [6, 14, 21] based on a few studies that
examined the efﬁcacy and safety of statins in prepubertal
children and children 8 to 10 years of age.
Currently, pravastatin is the only drug approved for
children with heterozygous FH (HeFH) as young as 8 years
of age, whereas other available statins are approved for
children older than 10 years. To date, available study data
are limited with regard to initiation of pharmacologic
treatment for TS 1 children, to what target LDL-C levels
should be reached for FH or other high risk children, and to
the long term effects of statins on growth and sexual
development. This may be due in part to the lack of
availability of an appropriate pediatric formulation for the
treatment of patients at younger ages. The development of
an appropriate pediatric formulation has been identiﬁed as
a current unmet pediatric need in cardiovascular products
by the Pediatric Working Party, a view also adopted and
published by the CHMP in November 2006 [8].
A chewable tablet formulation was developed as an
alternative treatment option, together with availability of a
lower-strength dose (5 mg) for use with younger pediatric
patients, as part of a Pediatric Investigation Plan recom-
mended in the Written Request by the EMEA Paediatric
Committee (PDCO) in 2009 [10]. In keeping with the need
to obtain appropriate data yet limit the exposure of younger
children, this 8-week pharmacokinetic and pharmacody-
namic (PK-PD) study used a population-based approach
recommended and endorsed by the Pediatric Committee.
The current study aimed to evaluate the short-term
efﬁcacy and tolerability of atorvastatin for HeFH children.
The patient cohort included a subgroup of TS 1 patients,
younger than those enrolled in most previous pediatric
studies, treated for 8-weeks with a chewable tablet devel-
oped for pediatric use. The chewable tablet formulation
was previously shown to have bioequivalence to the mar-
keted tablet formulation. Other objectives of this PK-PD
study including a description of the pharmacokinetics of
atorvastatin in children ages 6 to 17 years, characterization
of the relationship between atorvastatin and metabolite
exposure (pharmacokinetics), changes in lipid parameters
(pharmacodynamics), and possible recommendation of a
safe and efﬁcacious lower dose (\10 mg) for children ages
6 to 10 years, are described in a separate publication.
Methods
Study Design
From December 2008 to May 2009, 39 children and ado-
lescents with genetically conﬁrmed HeFH and an LDL-C
of 4 mmol/l (C155 mg/dl) or more were enrolled in this
8-week, open-label, uncontrolled study (NCT00739999).
The study participants were stratiﬁed into two cohorts
according to their Tanner stage, determined at the screen-
ing visit.
The study was conducted at three centers in Greece,
Norway, and Canada in compliance with the ethical prin-
ciples originating in or derived from the Declaration of
Helsinki and in compliance with all International Confer-
ence on Harmonization (ICH) Good Clinical Practice
(GCP) Guidelines. In addition, all local regulatory
requirements were followed, particularly those affording
greater protection of the study participants’ safety. Written
informed consent was obtained from each child’s parent or
legal guardian, and the minor’s assent also was required
when it could be obtained.
Patients
Eligible patients included girls and boys ages 6 to
\18 years. Children and adolescents 10 to 17 years of age
were to be at TS C2 in their development, whereas children
6 to 10 years of age were conﬁrmed to be at TS 1. All
patients had genetically veriﬁed HeFH, as evidenced by
LDL-C receptor mutation analysis [20] or by the lympho-
cyte test [3]. If subjects tested negative for the most
common LDL receptor mutations, detection of FH was to
be carried out by assaying LDL-C receptors on lympho-
cytes. In addition, all patients must have had a plasma
LDL-C level of 4 mmol/l (155 mg/dl) or higher at the
screening visit. The patients, otherwise in good health
based on the results of routine clinical laboratory tests,
physical examinations, and normal electrocardiograms
(ECGs) performed at screening, were judged by the
investigator to be good candidates for the study.
Subjects previously receiving probucol were required to
have stopped the treatment for 6 months or more to be
eligible. If a subject had been receiving statins previously,
a requisite washout period 6 weeks or longer was required
before entry to the study. Patients previously receiving
other antihyperlipidemic therapies were considered for
screening after a washout period of 4 weeks or longer
before entering this study. However, due to the competitive
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123enrollment between the three study sites, most, if not all,
the subjects enrolled in this study had not been previously
treated for dyslipidemia and therefore did not require a
washout period. Use of other prescription or over-the-
counter drugs and dietary supplements were stopped 7 days
or 5 half-lives (whichever was longer) before the ﬁrst dose
of study medication.
Treatment
Eligible patients entered the treatment phase of the study 1
to 4 weeks after the screening visit and received daily
atorvastatin for 8 weeks. The starting dose of atorvastatin
was 10 mg/day (formulated as a solid tablet) for the sub-
jects 10 to 17 years of age (i.e., TS C2) and 5 mg/day
(formulated as a chewable tablet for pediatric use) for the
subjects 6 to 10 years of age (i.e., TS 1). If a subject had
not attained the target plasma LDL-C level (\3.35 mmol/l
[\130 mg/dl]) at week 4, the atorvastatin dose could be
doubled. Compliance (deﬁned as 80–120% pill usage) was
assessed by examination of completed dosing diaries and
by tablet counts. Diets were not monitored during the study
period.
Efﬁcacy Assessments
The primary objective was to evaluate the effects of ator-
vastatin on plasma lipid levels after 8 weeks of treatment.
The efﬁcacy parameters were the mean percentage changes
from baseline for LDL-C, total cholesterol (TC), triglyc-
erides (TG), high density lipoprotein cholesterol (HDL-C),
very low density lipoprotein-cholesterol (VLDL-C), and
apolipoprotein (Apo) A-I, and Apo B. Because the patients
could have doubled their dose at week 4, additional
information is provided regarding those patients.
Fasting (at least 10 h from the last meal) blood samples
(2 ml) were taken for lipid proﬁling at screening (visit 1),
week 2 (visit 3), week 4 (visit 4), week 6 (visit 5), and
week 8 (visit 6). Fasting was optional at weeks 2 and 6
because clinic visits were in the afternoon. Lipid values
obtained at screening were considered as baseline values to
conserve the amount of blood drawn at week 1 (visit 2).
An optional assessment in the current study, ﬂow-
mediated dilation (FMD), was conducted at two of the
centers that had FMD measurement facilities available.
These measurements were designed to provide exploratory
information about endothelial function in the brachial
arteries via high-resolution ultrasound evaluation of arterial
diameter responses to increased blood ﬂow [2]. The sub-
jects were not required to participate in the FMD analysis.
The ultrasound machine was equipped with a 5- to
14-MHz vascular (near ﬁeld) transducer and vascular
imaging software. The ultrasound images of the brachial
artery were obtained during the diastolic phase of the
brachial artery (identiﬁed by R-wave of the electrocardio-
gram [ECG] or the smallest brachial artery at rest via visual
inspection). The sequential images of the brachial artery
enabled reconstruction of the brachial arterial lumen
diameter over the entire scan. Experienced sonographers
followed a standardized methodology, and scans were
batch analyzed at the individual FMD sites and blinded for
time point to minimize observer bias.
The FMD was assessed at weeks 0 and 8. For each scan,
baseline vessel size in millimeters, peak vessel size in
millimeters, and FMD as a percentage were entered into
the FMD database. From these parameters, FMD was
calculated as
Brachial FMD ¼½ ð maximum diameter
  baseline diameterÞ=baseline diameter 
  100%
Safety Assessments
Safety and tolerability were evaluated throughout the study
by review of patient reports, investigator observations, and
results of speciﬁc tests and measurements. The study
investigators assessed all adverse events (AEs) for level of
intensity and relationship to the study drug.
Routine clinical laboratory evaluations comprised
hematology and biochemistry tests performed at baseline;
at weeks 2, 4, and 6; and at the ﬁnal visit at week 8.
Urinalysis, physical examination (including height, weight,
and TS), and 12-lead ECG were performed at screening
and at week 8. Blood pressure and pulse rate were checked
at screening, week 4, and week 8. The clinical laboratory
sample analyses were performed by Quintiles Laboratories
in the United States and the United Kingdom.
Any safety laboratory values exceeding predeﬁned
thresholds were identiﬁed and tabulated. All such changes
considered clinically signiﬁcant were to be recorded as
AEs. If at any time during the study, a patient’s alanine
aminotransferase (ALT) or aspartate aminotransferase
(AST) plasma levels increased to more than three times the
upper limits of normal (ULN), the patient was to be
scheduled for a repeat laboratory measurement within
1 week (±3 days). If the repeat value still exceeded
3 9 ULN, the patient’s medication was to be reduced by
50% and a repeat laboratory measurement completed after
2 weeks of therapy with the reduced dose. If the repeat
value still exceeded 3 9 ULN, the patient was to be
withdrawn from the study, and a ﬁnal physical examination
was to be performed. This persistent elevation in ALT or
AST was to be reported as a clinically important AE. A
patient was discontinued immediately from the study if the
creatine phosphokinase (CPK) level was elevated to
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12310 9 ULN accompanied by muscle pain, tenderness, or
weakness. A persistent plasma CPK elevation of
10 9 ULN or more without muscle pain, tenderness, or
weakness also was designated as a prespeciﬁed reason for
study drug discontinuation.
Statistical Analysis
The analysis population was deﬁned as all the enrolled
subjects who received one or more doses of the study drug
and had one or more pharmacodynamic parameter mea-
surements. Change and percentage change from baseline in
the lipid parameters were summarized using descriptive
statistics by cohort over time.
Results
Patient Accounting and Demographics
Of the 45 individuals screened in this study, 39 pediatric
patients with HeFH were treated, comprising 15 children at
TS 1 and 24 adolescents at TS C2. All the patients com-
pleted the study. Table 1 shows that all the patients in both
cohorts were white and that the proportions of males and
females in the two cohorts were similar. Two TS 1 patients
were older than 10 years and therefore noted as protocol
deviations. Evaluation by a pediatric endocrinologist
determined that neither patient had abnormalities in any
system.
The patients were treated for a median of 55 days
(range, 46–77 days) in the TS 1 cohort and 61.5 days
(range, 40–77 days) in the TS C2 cohort. The atorvastatin
dose levels were doubled after the week 4 visit for more
than half of the patients (10 of 15 TS 1 patients and 15 of
24 TS C2 patients). Adherence to the study drug regimen
was good, with only four patients having a compliance rate
lower than 80% (range, 73–80%). A total of 16 subjects
(2 subjects of TS 1 and 14 subjects of TS 2) from one study
center in Canada had visit schedules outside the 7-day
range speciﬁed by the protocol due to various family or
study center scheduling-related reasons.
Efﬁcacy
Table 2 presents information for all the lipid parameters
measured by the Tanner stage cohort and within those
cohorts by ﬁnal dose at week 8. The baseline mean LDL-C
value was 5.87 mmol/l for the TS1 cohort and 5.81 mmol/l
for the TS C2 cohorts. Administration of daily atorvastatin
for 8 weeks resulted in reduced LDL-C, TC, and TG in TS
1 and TS C2 children (Table 2). Across both cohorts, the
mean plasma levels of LDL-C fell from baseline to week 8
by approximately 40%, and TC fell by approximately 35%.
The mean reductions in LDL-C and TC were comparable
across both cohorts at week 8. The baseline TG levels all
were within the normal range, with TS C2 patient levels
slightly higher than TS 1 patient levels (1.14 vs. 0.89 mmol/
l). Similarly, a larger reduction in the mean plasma TG level
was observed in the TS C2 patients than in the TS 1 patients
(-21.05% vs. –6.02%). The baseline HDL levels were
within the normal range, with the TS C2 patients having
slightly lower values than the TS 1 cohort (1.18 vs.
1.35 mmol/l). In both cohorts, nonsigniﬁcant reductions
from baseline in plasma HDL-C levels were observed, dri-
ven by changes in HDL-C among patients whose atorva-
statin dose was doubled at week 4.
Over the 8-week study period, LDL-C/HDL-C ratios
decreased across both cohorts (data on ﬁle). In both cohorts
at study end, treatment with atorvastatin also had produced
substantial reductions in the mean plasma levels of VLDL-
C, LDL-C/HDL-C, and Apo B, as well as modest reduc-
tions in Apo A-I. The VLDL-C reductions appeared to be
greater in the TS C2 cohort than in the TS 1 cohort
(-52.84% vs. -37.63%).
Table 2 also shows that patients who did not achieve the
recommended treatment goal at week 4 (those whose dose
Table 1 Baseline patient demographics
Parameter Tanner stage 1
(n = 15)
Tanner stage C2
(n = 24)
Age (years)
6–8 7 0
9–10 6 3
11–14 2
a 14
15–17 0 7
Mean (SD), years 8.7 ± 1.8 13.5 ± 1.9
Range 6–12 10–17
Male: n (%) 8 (53) 12 (50)
Race: n (%)
White 15 (100) 24 (100)
Weight (kg)
Mean (SD) 32.6 ± 8.7 54.3 ± 14.7
Range 25.0–54.2 32.0–99.4
b
Height (cm)
Mean (SD) 137.4 ± 9.0 160.1 ± 10.2
Range (119.0–151.0) (137.5–182.0)
BMI (kg/m
2)
Mean (SD) 17.1 ± 3.0 20.9 ± 4.2
Range (13.2–24.7) (15.8–32.5)
BMI body mass index
a These patients were captured as protocol deviations
b One male weighed 99.4 kg, which was above the 95th percentile for
his age. He was included in the study and captured as a protocol
deviation
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123was doubled for the remainder of the study) were at a much
higher baseline LDL-C level regardless of Tanner stage
cohort. The reductions in mean plasma levels of LDL-C,
TC, and TG tended to be greater in the subjects whose
atorvastatin dose was doubled at week 4 than in the sub-
jects who continued to receive their original dose.
More variable results were collected for the other lipid
parameters regarding atorvastatin dose level and cohort.
For the TS C2 subjects, the reductions in VLDL-C and
Apo B were similar in the two dose groups. However, for
the TS 1 subjects, the decrease in mean plasma VLDL-C
(-50.3% vs. -12.3%) and Apo B (-39.6% vs. -27.4%)
levels were greater among those whose dose had been
doubled after the week 4 visit than among those who
continued to receive their initial dose. For both cohorts, the
decrease in Apo A-1 was somewhat larger among those
whose dose had been doubled after the week 4 visit than
among those who continued to receive their initial dose
(-3.4% vs. -1.2% for TS 1; -4.8% vs. -2.6% for TS
C2). The HDL-C levels were slightly improved in the
patients who continued to receive their starting dose but
slightly decreased for those whose dosage was doubled.
Temporal analysis of lipid parameters showed that the
mean values for LDL-C and TC decreased by week 2
Table 2 Mean (SD) percentage changes in lipid parameters from baseline to week 8 by atorvastatin dose assignment in children and adolescents
with heterozygous familial hypercholesterolemia
Variable Tanner stage 1 Tanner stage C2
Patients who
stayed at 5 mg
(n = 5)
Patients who
increased to
10 mg (n = 10)
All patients
(n = 15)
Patients who
stayed at 10 mg
(n = 9)
Patients who
increased to 20 mg
(n = 15)
All patients
(n = 24)
Low density lipoprotein cholesterol (mmol/l)
Baseline mean 4.87 ± 0.48 6.37 ± 1.10 5.87 ± 1.18 5.11 ± 0.65 6.23 ± 1.00 5.81 ± 1.03
End point mean 3.06 ± 0.54 3.66 ± 0.80 3.46 ± 0.76 3.12 ± 0.40 3.63 ± 0.43 3.44 ± 0.48
% Change from baseline -36.78 ± 11.16 -42.70 ± 6.45 -40.72 ± 8.41 -38.45 ± 7.84 -40.39 ± 11.71 -39.66 ± 10.28
Total cholesterol (mmol/l)
Baseline mean 6.76 ± 0.46 8.58 ± 1.06 7.97 ± 1.25 6.92 ± 0.71 8.40 ± 1.10 7.84 ± 1.20
End point mean 4.87 ± 0.39 5.39 ± 0.75 5.21 ± 0.69 4.66 ± 0.65 5.18 ± 0.49 4.99 ± 0.60
% Change from baseline -27.80 ± 5.56 -37.17 ± 5.28 -34.05 ± 6.90 -32.43 ± 8.53 -37.45 ± 9.89 -35.57 ± 9.54
Triglycerides (mmol/l)
Baseline mean 0.76 ± 0.15 0.95 ± 0.27 0.89 ± 0.25 1.03 ± 0.37 1.20 ± 0.50 1.14 ± 0.46
End point mean, mmol/L 0.79 ± 0.34 0.79 ± 0.23 0.79 ± 0.26 0.72 ± 0.24 0.92 ± 0.42 0.84 ± 0.37
% Change from baseline 1.69 ± 31.48 -9.88 ± 33.31 -6.02 ± 32.06 -20.94 ± 39.24 -21.11 ± 23.85 -21.05 ± 29.69
High density lipoprotein cholesterol (mmol/l)
Baseline mean 1.35 ± 0.12 1.45 ± 0.29 1.41 ± 0.25 1.17 ± 0.18 1.18 ± 0.23 1.18 ± 0.21
End point mean 1.39 ± 0.31 1.38 ± 0.21 1.38 ± 0.24 1.24 ± 0.34 1.11 ± 0.23 1.16 ± 0.28
% Change from baseline 2.50 ± 15.02 -2.84 ± 14.49 -1.06 ± 14.36 5.99 ± 21.02 -5.19 ± 17.76 -1.00 ± 19.40
Very low density lipoprotein cholesterol (mmol/l)
Baseline mean 0.54 ± 0.15 0.76 ± 0.30 0.69 ± 0.27 0.65 ± 0.11 0.99 ± 0.31 0.86 ± 0.30
End point mean 0.42 ± 0.20 0.35 ± 0.15 0.37 ± 0.16 0.30 ± 0.12 0.44 ± 0.21 0.39 ± 0.19
% Change from baseline -12.31 ± 57.38 -50.29 ± 21.44 -37.63 ± 39.75 -53.61 ± 19.21 -52.38 ± 29.34 -52.84 ± 25.55
Apolipoprotein A-I (g/l)
Baseline mean 1.42 ± 0.20 1.45 ± 0.20 1.44 ± 0.19 1.29 ± 0.20 1.24 ± 0.15 1.26 ± 0.17
End point mean 1.40 ± 0.14 1.40 ± 0.20 1.40 ± 0.18 1.24 ± 0.25 1.17 ± 0.22 1.20 ± 0.23
% Change from baseline -1.24 ± 8.49 -3.37 ± 9.35 -2.66 ± 8.82 -2.60 ± 20.22 -4.82 ± 16.13 -3.98 ± 17.37
Apolipoprotein B (g/l)
Baseline mean 1.09 ± 0.13 1.49 ± 0.24 1.35 ± 0.28 1.26 ± 0.14 1.52 ± 0.18 1.42 ± 0.21
End point mean 0.79 ± 0.12 0.90 ± 0.15 0.86 ± 0.15 0.85 ± 0.10 1.04 ± 0.26 0.97 ± 0.23
% Change from baseline -27.39 ± 5.97 -39.59 ± 5.83 -35.52 ± 8.22 -31.94 ± 11.64 -31.26 ± 18.57 -31.51 ± 16.04
Low density lipoprotein cholesterol/high-density lipoprotein-cholesterol
Baseline mean 3.63 ± 0.39 4.63 ± 1.69 4.30 ± 1.46 4.46 ± 0.79 5.41 ± 1.11 5.05 ± 1.09
End point mean 2.33 ± 0.72 2.70 ± 0.77 2.58 ± 0.75 2.63 ± 0.56 3.44 ± 0.87 3.13 ± 0.85
% Change from baseline -36.49 ± 16.48 -39.95 ± 11.02 -38.80 ± 12.59 -40.82 ± 8.88 -35.84 ± 12.54 -37.71 ± 11.37
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123among all TS 1 and TS C2 subjects, whereas TG and HDL-
C varied considerably from week to week (Fig. 1). Plasma
LDL-C and TC levels continued to decrease over the
8-week study period for the patients whose dose had been
doubled but exhibited maximum reductions by week 4 for
those who remained at their initial dose (Fig. 2).
Flow-mediated dilation data were provided for 11 of 15
TS 1 subjects and for 17 of 24 TS C2 subjects. For the TS 1
cohort, FMD values varied widely, ranging from 0.0% to
11.5% (mean, 6.3%) at baseline and from 0.0% to 12.0%
(mean, 5.5%) at week 8. Similar wide variations in FMD
values were observed for the TS C2 cohort, ranging from
0.0% to 10.0% (mean, 3.9%) at baseline and from 2.9% to
9.3% (mean, 4.9%) at week 8.
Safety
The safety results and the most commonly reported AEs for
the two cohorts are shown in Table 3. No deaths, serious
AEs, or premature discontinuations were reported. Overall,
no difference in safety or tolerability was observed
between the younger and older cohorts. A total of 16 AEs
were reported from 9 patients in the TS 1 cohort (4 of
which were considered treatment related) and 17 AEs from
13 patients in the TS C2 cohort (2 of which were consid-
ered treatment related). The treatment-emergent AEs of
abdominal pain, nausea, vomiting, and headache were
experienced by two TS 1 patients, and treatment-emergent
AEs of increased plasma ALT levels were experienced by
two TS C2 patients. A moderate but transient increase in
blood creatinine, observed in a 9-year-old girl, was attrib-
uted to reduced water intake.
All treatment-emergent AEs were mild to moderate in
intensity. The two episodes of increased plasma ALT levels
occurred in two 13-year-old girls. One girl returned to
‘‘normal’’ levels during the study period. The other girl had
a slightly elevated ALT level at the ﬁnal visit. None of the
ALT values at any of her other visits were elevated. No
vital sign or ECG readings were documented as AEs.
Discussion
The pediatric patients with HeFH who participated in this
study presented with very high LDL-C and TG levels and
an HDL-C level within the normal range. The observed
reductions in lipid values associated with a pediatric for-
mulation of atorvastatin in the prepubertal TS 1 patients in
this study were consistent with those seen in the TS C2
patients and with reductions previously reported for other
older pediatric populations [1, 7, 14, 16, 19, 21].
Overall, the mean values for LDL-C, TC, VLDL-C, and
Apo B had decreased to a clinically signiﬁcant extent by
Fig. 1 Mean percentage change from baseline in lipid parameters of
children and adolescents with heterozygous familial hypercholester-
olemia who received daily atorvastatin 5 to 10 mg Tanner stage (TS)
1 patients or 10 to 20 mg (TS C2 patients) for 8 weeks. TS 1 patients
were treated initially with atorvastatin 5 mg/day and TS C2 patients
with 10 mg/day. Doses were doubled at week 4 if the low density
lipoprotein cholesterol (LDL-C) target concentration (\130 mg/dl
[3.35 mmol/l]) was not achieved
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123week 2 among all TS 1 and TS C2 patients. The patients in
each cohort whose dose was doubled had generally higher
mean baseline lipid values than those not requiring a dose
increase. For these subjects, additional improvements in
lipid proﬁle were observed as early as 2 weeks after the
dose escalation. The mean percentage decreases in lipid
parameters generally were similar for the two Tanner stage
cohorts regardless whether the subjects remained at their
initial dose or received a doubled dose. Furthermore,
atorvastatin (5–10 mg for the TS 1 patients and 10–20 mg
for the TS C2 patients) was well tolerated in this study, and
no safety issues were identiﬁed over the 8-week study
duration. No clinically signiﬁcant difference in tolerability
or safety was observed between the younger and older
cohorts.
Previous evidence has demonstrated the efﬁcacy and
safety of atorvastatin for pediatric patients. In a double-
blind, placebo-controlled clinical trial involving 187 chil-
dren 10 to 17 years of age at TS C2 with known familial
hypercholesterolemia or severe hypercholesterolemia, the
administration of atorvastatin (10–20 mg/day) for
12 months proved to be effective and well tolerated for the
treatmentofelevated lipidlevelsinboththe childrenandthe
adolescents [21]. At week 26, atorvastatin 10 to 20 mg
compared with placebo was associated with signiﬁcant
reductions in LDL-C (-40% vs. -0.4%), TC (-32% vs.
-1.5%), TG (-12% vs. ?1.0%), and Apo B (-34% vs.
?0.7%). Also HDL-C increased with atorvastatin compared
with placebo (?2.8% vs. -1.8%).
In a compassionate use study, 46 children (11 age
\10 years and 35 ages 11–17 years) with severe dyslipi-
demia, including 30 with homozygous FH, atorvastatin was
well-tolerated up to 3 years at titrated doses across the full
available 10- to 80-mg dose range (data on ﬁle). Although
the modiﬁcation in lipid levels after the treatment of pre-
pubertal TS 1 patients with atorvastatin observed in this
study was not markedly different from that previously
observed in other older pediatric populations [1, 7, 14, 16,
19, 21], several methodologic aspects of our study merit
discussion. One limitation of the study was the necessarily
small sample size. Although the sample small size was
small, all the patients completed the study, treatment
compliance was high. In addition, no data points were
missing. Therefore, no imputations were necessary. Fur-
thermore, the study was an open-label uncontrolled study
that included only patients with FH.
However, as described earlier, in keeping with the need
to limit the exposure of younger children, the design of this
8-week pharmacokinetic and pharmacodynamic study was
thoroughly discussed with PDCO and endorsed by it. This
study used well-established and validated modern popula-
tion pharmacokinetic modeling approaches [9, 11], taking
the minimal blood samples required from each child while
obtaining robust population pharmacokinetic data.
Although the study design and small sample size pre-
cludes any deﬁnitive statements, overall, the PK of ator-
vastatin in this subgroup of pediatric patients does not
appear to differ markedly from that in adults. The most
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123important ﬁnding in the population PK analysis was that
atorvastatin clearance (CL/F) in pediatric subjects appeared
similar to that in adults when scaled by subject weight.
Body weight also was the only covariate inﬂuencing ator-
vastatin CL/F [12]. Other covariates such as age, gender,
and Tanner stage had little inﬂuence on the PK parameters
tested. At week 8, on the average, the percentage change
from baseline was approximately 40% for LDL-C and 30%
for TC over the range of atorvastatin and o-hydroxyator-
vastatin exposures [12].
Overall, there appeared to be no evidence of variations
in lipid effects between Tanner stage patients or across the
range of atorvastatin and o-hydroxyatorvastatin exposures.
This likely is due to the Tanner stage-dependent doses and
the titration dosing design in this study, in which the
patients were evaluated for dose escalation based on target
levels or reduction in LDL-C.
Approximately two-thirds of both Tanner stage cohorts
(10 of 15 TS 1 patients and 15 of 24 TS C2 patients) in this
study had a much higher LDL-C at baseline and required
up-titration at week 4. For these patients, doubling the dose
to 10 or 20 mg (TS 1 and TS [2 cohorts, respectively)
provided additional LDL-C reduction. Approximately 50%
of the patients reached the target 130 mg/dl (3.35 mmol/l)
at week 8. Currently, the evidence is limited regarding
what target LDL-C level should be attained [5, 15]. Both
the American Heart Association [17] and the American
Academy of Pediatrics (AAP) [4] have recommended that
LDL-C target levels as low as 130 mg/dl (3.35 mmol/l)
should be set for HeFH children. In clinical practice, a
prescribing physician may consider titrating to a higher
atorvastatin dose than those used in this study (i.e., above
10 mg/day for TS 1 and above 20 mg/day for TS C2) to
achieve the LDL-C target, taking into account patient risk
and beneﬁt proﬁles.
Use of plasma lipid levels as a reliable surrogate marker
for coronary heart disease is well established for adults, and
the main target of lipid-lowering management depends on
the patient’s level of risk. Recent evidence of statin use in
children 8 to 17 years of age also indicates that a moderate
reduction in LDL-C of 25% to 30% over a 2-year period
signiﬁcantly decreases the rate of carotid artery intima
thickening, a parameter often used as a predictor of coro-
nary risk in adults [21].
To provide additional exploratory data showing the
effects of atorvastatin on endothelial function in this popu-
lation, a separate analysis of FMD was undertaken. Previous
studies have shown signiﬁcant improvement in endothelial
dysfunction toward normal levels after short-term statin
therapy in children with FH [20]. The current substudy
showed a wide range of observed individual FMD values at
baseline and at week 8 for both cohorts, but no meaningful
conclusions could be drawn. Finally, the short time frame of
this study precluded safety assessmentsof atorvastatin in TS
1 children with respect to growth and development.
In conclusion, clinically meaningful reductions in LDL-
C, TC, VLDL-C, and Apo B were observed with atorva-
statin in TS 1 and TS C2 patients with HeFH. Atorvastatin
also was well tolerated in this population, and no patients
withdrew prematurely from this 8-week study. However,
the effect that long-term use of statins has on the TS 1
patient is not established, and treatment should be admin-
istered under close pediatric supervision.
Table 3 Incidence of all-cause TEAEs (and treatment-related AEs)
reported in patients during 8 weeks of atorvastatin treatment
AEs No. evaluable patients
Tanner stage 1
(n = 15)
Tanner stage C2
(n = 24)
All 9 (2) 13 (2)
Serious TEAEs 0 0
Severe or very severe TEAEs 0 0
Discontinued due to a TEAE 0 0
MedDRA preferred term
Nasopharyngitis 1 2
Viral upper respiratory
tract infection
30
Headache 2 (1) 1
Gastroenteritis 1 1
Alanine aminotransferase
increased
0 2 (2)
Abdominal pain 1 (1) 0
Nausea 1 (1) 0
Toothache 0 1
Vomiting 1 (1) 0
Pain 0 1
Bronchopneumonia 1 0
Ear infection 0 1
Gastritis viral 1 0
Inﬂuenza 0 1
Lower respiratory tract
bacterial infection
01
Tonsillitis 0 1
Viral rhinitis 1 0
Hand fracture 0 1
Blood creatinine increased 1 0
Arthralgia 0 1
Musculoskeletal pain 0 1
Pain in extremity 0 1
Asthma 1 0
Rhinitis allergic 0 1
Urticaria 1 0
AE adverse event; MedDRA Medical Dictionary for Regulatory
Activities, version 12.0; TEAEs treatment emergent adverse events
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